¹«ÓÃϵͳ¹¤³Ìʦ ÃæÒé ÊÕ²Ø ÉêÇëְλ
Ê×Ò³ > Ì©ÖÝÕÐÆ¸ > ¹«ÓÃϵͳ¹¤³Ìʦ

¹«ÓÃϵͳ¹¤³Ìʦ

Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾

Ë¢ÐÂÓÚ£º2019-04-19±»ä¯ÀÀ£º1868´Î

ÃæÒé

²»ÏÞ / ´óר / ÐÔ±ð²»ÏÞ / ÃæÒé / ²»ÏÞµ½¸Ú

Ì©ÖÝ-º£Áê £¨Ì©ÖÝÒ½Ò©¸ßм¼Êõ²úÒµÔ°¿Ú̩·Î÷²à½¼Ò·¶«²àG79´± £© Éϰà·Ïß²éѯ

ÕÐÆ¸ÃæÒé

³Â
ְλ·¢²¼ÈË£º³ÂÏÈÉú

139****6549,052****713092 ÏÔʾºÅÂë

(ÁªÏµÊ±Çë˵Ã÷ÊÇÔÚÐÂÌ©ÖÝÈ˲ÅÍøÉÏ¿´µ½µÄ)

´òµç»°Ç°ÏÈͶ¸ö¼òÀú£¬»ñµÃÃæÊԵijɹ¦ÂÊÔö¼Ó30%

Ì©ÖÝÈ˲ÅÍøÌáʾ£ºÌ©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÎÞȨÊÕÈ¡ÈκηÑÓã¬Çë¹ã´óÇóÖ°Õß¼ÓÇ¿×ÔÎÒ±£»¤Òâʶ£¬°´ÀͶ¯·¨¹æ±£»¤×ÔÉíÈ¨Òæ£¬¾¯ÌèÐé¼ÙÕÐÆ¸,±ÜÃâÉϵ±ÊÜÆ­£¡ ¾Ù±¨´Ëְλ
ְλÃèÊö

¸ÚλְÔð£º1ʵʩ¹«ÓÃϵͳ(º¬¿Õµ÷¼°Ë®´¦Àíϵͳ)&
#160;
É豸ÉèÊ©µÄ²Ù×÷ÔËÐÐ¼à¿ØÈÕ³£±£Ñø¹¤×÷£»

2Ö´Ðй«ÓÃϵͳ(º¬¿Õµ÷¼°Ë®´¦Àíϵͳ)±£ÑøºÍάÐÞ¹¤×÷£»

3²ÎÓëÉ豸ÉèÊ©µÄÈ·ÈϹ¤×÷£»

4²ÎÓëÖ´Ðй«ÓÃϵͳ(º¬¿Õµ÷¼°Ë®´¦Àíϵͳ)´óÖÐÐ޼ƻ®£»

5²ÎÓ빫ÓÃϵͳ(º¬¿Õµ÷¼°Ë®´¦Àíϵͳ)µÄ°²×°µ÷ÊÔÑéÊսӹܵŤ×÷£»

6²ÎÓëÏà¹Ø×¨ÒµµÄ¼¼ÄÜÅàѵ£»

8Íê³ÉÁìµ¼½»°ìµÄÆäËüÈÎÎñ¡£
&
#160;
&
#160;
ÈÎÖ°ÒªÇó£º1ÖÐר¼°ÒÔÉÏѧÀú£¬»úеµçÆøÅ¯Í¨µÈÏà¹Ø×¨Òµ¡£
2ÓÐÒ©³§ÖÆÒ©ÓÃË®´¦ÀíÖÐÑë¿Õµ÷²Ù×÷»ò¶¯Á¦É豸²Ù×÷¹¤×÷¾­ÑéÓÅÏÈ£»

3»ý¼«½øÈ¡£
¬¾ßÓÐÍŶÓÒâʶ¼°½ÏÇ¿µÄ·þÎñÒâʶ£»

4½ÏÇ¿ÔðÈÎÐÄ£¬¶Ô¹¤×÷ÈÏÕæ¸ºÔð£¬Äܹ»³Ô¿àÄÍÀÍ£¬Ñ§Ï°ÄÜÁ¦Ç¿¡£
ÓÉÓÚÓʼþ½Ï¶à£¬ÇëÓÐÒâÏòÕß·¢ËͼòÀúÖÁhr.
taizhou#,Ç뽫#¸ÄΪ@£¬Ð»Ð»¡£

¹«Ë¾¼ò½é
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾ÓÚ2015ÄêÈëפ̩ÖÝÊÐÖйúÒ½Ò©³Ç£¬×¢²á×ʱ¾2000ÍòÃÀÔª¡£¹«Ë¾Ö÷Òª´Óʵ¥¿¹Ò©ÎïÉú²ú£¬Í¶×Ê×ܶî2ÒÚÃÀÔª£¬Ä⽨³§·¿Ãæ»ý3ÍòÓàÆ½·½£¬½¨Éè·ûºÏGMP±ê×¼µÄ¹ú¼ÊÏȽøµÄ¿¹ÌåÒ©ÎïÖÆ±¸Ìåϵ£¬ÒÔÆÚ´òÔì¹úÄÚ¿¹ÌåÒ©ÎïÉú²ú¸ßµØ¡£Âõ²©Ì«¿ÆÒ©ÒµÓÉÉϺ£ÕŽ­ÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾£¨¿¹ÌåÒ©ÎïÓë°ÐÏòÖÎÁƹú¼ÒÖØµãʵÑéÊÒ£©¿¹ÌåÑз¢ÍŶÓÌṩһվʽƽ̨·þÎñ£¬ÖÂÁ¦ÓÚʵÏÖһϵÁÐÖØÁ¿¼¶¹ú¼Ò´´Ð¿¹ÌåÒ©ÎïµÄ²úÒµ»¯¡£ÏÖÓÐÆ·ÖÖ£ºÖÎÁƽáÖ±³¦°©µÄÖØ×鿹EGFRÈËÊóǶºÏµ¥¿Ë¡¿¹Ì壬ÖÎÁÆÒøÐ¼²¡µÄÖØ×éÈËLFA3-¿¹ÌåÈںϵ°°×µÈ¡£TaizhouMabtechPharmaceuticalCo.,Ltd.joinedtheChinaMedicalCity(CMC)in2015withregisteredcapitalofUSD20million,expandinganationalhighlandformonoclonalantibodymedicinemanufacturingbyestablishinginternationallyadvancedantibodymedicinemanufacturesystemwithadoptedcGMPstandards,withatotalinvestmentofUSD200million.Supportedbytheone-stopplatformfortherapeuticmAbmedicinedevelopmentprovidedbyZJ-BioR&DTeam(StateKeyLaboratoryofAntibodyMedicineandTargetedTherapy),TaizhouMabtechPharmaceuticsCo.,Ltdisdedicatedtoindustrializationofaseriesof¡°blockbuster¡±innovativeantibodydrugs.Existingvarieties:recombinantanti-EGFRhuman/mouse-chimericmonoclonalantibodyforthetreatmentofcolorectalcancer,recombinanthumanLFA3-antibodyfusionproteinforthetreatmentofpsoriasis,etal.
¸Ã¹«Ë¾µÄÆäTAְλ
Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
  • ÖÆÔìÒµ
  • ÍâÉÌͶ×ÊÆóÒµ
  • Ì©ÖÝ-º£Áê
  • 100-1000ÈË
0%¼òÀú·´À¡ÂÊ
0ƽ¾ù»Ø¸´Ê±³¤
0¸öÕÐÆ¸Ö°Î»
ְλÃû³Æ£º¹«ÓÃϵͳ¹¤³Ìʦ
¹«Ë¾Ãû³Æ£º Ì©ÖÝÂõ²©Ì«¿ÆÒ©ÒµÓÐÏÞ¹«Ë¾
 
ÏàËÆÖ°Î»
  • ¹¤³Ìʦ
    ÃæÒé Ì©ÖÝ-Ì©ÐË
    ½­ËÕÁªÊ¢±£°²·þÎñÓÐÏÞ¹«Ë¾